Overview

Efficacy of Isradipine in Early Parkinson Disease

Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
Phase:
Phase 3
Details
Lead Sponsor:
University of Rochester
Collaborators:
Michael J. Fox Foundation for Parkinson's Research
National Institute of Neurological Disorders and Stroke (NINDS)
The Parkinson Study Group
Treatments:
Isradipine